

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

13 Jun 2026

### A Comparative Study of the Effect of Two Concentrations of Dextrose Injection (12.5% And 25%) on Pain and Function of Patients with Rotator Cuff Tendinopathy of The Shoulder

#### Protocol summary

##### Study aim

Evaluation of the effect of injection of 12.5% and 25% dextrose prolotherapy under ultrasound guidance on pain and function in rotator cuff tendinopathy

##### Design

Semi-experimental clinical trial with control group, with parallel groups, unblinded, computerized randomization, phase 3 on 66 patients

##### Settings and conduct

Selection of participants from people who come to the sports medicine department of Imam Hospital due to shoulder pain First group: injection of 2 ml of 25% dextrose prolotherapy solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) in the clinic Second group: injection of 2 ml of 12.5% Prolotherapy dextrose solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) in the clinic Control group: home-based exercise therapy

##### Participants/Inclusion and exclusion criteria

Inclusion Criteria: Adults (over 20 years) Chronic shoulder pain for more than six months Shoulder ultrasound showing chronic tendinopathy of the supraspinatus tendon The average intensity of shoulder pain is more than 3 points on the ten-point Visual Analog Scale Exclusion Criteria: Associated with adhesive capsulitis Shoulder joint replacement Shoulder surgery or arthroscopy of the injured shoulder within the past year Any kind of injection in the shoulder joint within the last three months. Neurological disease that causes weakness on the affected side Impaired cognitive function

##### Intervention groups

First group: injection of 2 ml of 25% dextrose prolotherapy solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) Second group: injection of 2 ml of 12.5% Prolotherapy dextrose solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) Control

group: exercise therapy

##### Main outcome variables

Primary outcome: mean score in shoulder pain and disability index Secondary outcomes: shoulder active range of motion, supraspinatus tendon thickness

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20230821059204N2**

Registration date: **2023-10-12, 1402/07/20**

Registration timing: **prospective**

Last update: **2023-10-12, 1402/07/20**

Update count: **0**

##### Registration date

2023-10-12, 1402/07/20

##### Registrant information

##### Name

Hanieh Ahmadi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 11 3336 6552

##### Email address

h.ahmadi@mazums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-10-22, 1402/07/30

##### Expected recruitment end date

2024-03-19, 1402/12/29

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

A Comparative Study of the Effect of Two Concentrations of Dextrose Injection (12.5% And 25%) on Pain and Function of Patients with Rotator Cuff Tendinopathy of The Shoulder

**Public title**

Effect of Dextrose Injection in Rotator Cuff Tendinopathy of The Shoulder

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Adults (over 20 years) Chronic shoulder pain for more than six months Shoulder ultrasound of the supraspinatus tendon showing chronic tendinopathy such as a tear or tendinosis The average intensity of shoulder pain is more than 3 points on the ten-point Visual Analog Scale (VAS) Agreeing and complying with our study protocol The possibility of signing an informed consent form

**Exclusion criteria:**

Associated with adhesive capsulitis and limited range of motion of the shoulder Shoulder joint replacement Shoulder surgery or arthroscopy of the injured shoulder within the past year Injection of steroid, hyaluronic acid or platelet-rich plasma or any type of prolotherapy injection in the shoulder joint within the last three months Neurological disease that causes weakness on the affected side Impaired cognitive function and inability to complete the questionnaire Concurrent participation in another clinical trial

**Age**

From **20 years** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **66**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization will be done using computer generated random numbers. Based on the selected numbers, the participants will be assigned to a 12.5% hypertonic dextrose prolotherapy group, another 25% hypertonic dextrose prolotherapy group, and a control group of exercise therapy.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Parallel

**Other design features**

In the first group, 2 ml of 25% dextrose Prolotherapy solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) and in the second group 2 ml of 12.5% dextrose Prolotherapy solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) will be injected. The control group will be exercise therapy.

**Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Mazandaran University of Medical Sciences, Imam Hospital

**Street address**

Serah Joibar, the beginning of Vali Asr Highway, the headquarters of Mazandaran University of Medical Sciences and Health Services

**City**

Sari

**Province**

Mazandaran

**Postal code**

3397148157

**Approval date**

2023-04-19, 1402/01/30

**Ethics committee reference number**

IR.MAZUMS.IMAMHOSPITAL.REC.1402.14941

**Health conditions studied****1****Description of health condition studied**

Rotator cuff tendinopathy of the shoulder

**ICD-10 code**

S46.0

**ICD-10 code description**

Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder

**Primary outcomes****1****Description**

Average score in the Shoulder Pain and Disability Index (SPADI) of the injured shoulder

**Timepoint**

At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention

**Method of measurement**

The Shoulder Pain and Disability Index (SPADI) is a self-administered assessment tool used to measure shoulder pain and disability. It has five pain items and eight disability items measured on the Visual Analogue Score. Pain and disability subscales are calculated as the mean of the corresponding items on a 0-100 scale, with the highest score indicating the most severe pain and disability. In this study, the total outcome score used for statistical analysis will be calculated as the sum of pain and disability subscales.

## Secondary outcomes

### 1

#### Description

Active range of motion of the shoulder

#### Timepoint

At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention

#### Method of measurement

Active shoulder range of motion, i.e., forward flexion, internal rotation, external rotation, and abduction in standing position, will be assessed using a goniometer. Patients will move their shoulders slowly until they reach an angle at which pain is felt, and this movement will be performed three times to record the average value of the angle.

### 2

#### Description

Supraspinatus tendon thickness

#### Timepoint

At the beginning of the study before the start of the intervention and at the end of the second and sixth weeks after the intervention

#### Method of measurement

Using ultrasound, the maximum thickness of the supraspinatus tendon will be measured in millimeters.

## Intervention groups

### 1

#### Description

Intervention group 1: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension, arm flexion, and hand to hip touch to obtain a longitudinal view of the supraspinatus tendon. A prolotherapy injection session will be performed under ultrasound guide in aseptic conditions using a 23-G needle to the insertion site of the supraspinatus tendon. In the first group, 2 ml of 25% Prolotherapy dextrose solution (containing 1 ml of 50% dextrose and 1 ml of 2% lidocaine) will be injected.

#### Category

Treatment - Drugs

### 2

#### Description

Intervention group 2: The injection will be performed under ultrasound guide by a sports medicine specialist. Patients will maintain an upright sitting position with shoulder extension, arm flexion, and hand to hip touch to obtain a longitudinal view of the supraspinatus tendon. A prolotherapy injection session will be performed under ultrasound guide in aseptic conditions using a 23-G needle to the insertion site of the supraspinatus tendon. In the first group, 2 ml of 12.5% Prolotherapy dextrose solution (containing 0.5 ml of 50% dextrose and 1.5 ml of 2% lidocaine) will be injected.

#### Category

Treatment - Drugs

### 3

#### Description

Control group: The control group will be given exercise therapy, which exercises will be given to the patient in a booklet, and they will be taught in each visit that the exercises in the first week include correcting the position of the scapula and the shrug of the scapula; in the second week includes external rotation at zero degrees; in the third week, it includes internal rotation at 0 degrees, and in the fourth week, it includes boat movement at 45 degrees, boat movement at 90 degrees, anterior shoulder stretching and trunk stretching in a sitting position.

#### Category

Treatment - Other

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Department of Sports Medicine, Mostafavian Clinic, Sari Imam Khomeini Hospital

##### Full name of responsible person

Hanieh Ahmadi

##### Street address

Sports Medicine Department, Mostafavian Clinic, Razi No. 3 Alley, Razi St., Sari

##### City

Sari

##### Province

Mazandaran

##### Postal code

4816868890

##### Phone

+98 11 3336 6552

##### Email

h.ahmadi@mazums.ac.ir

## Sponsors / Funding sources

# 1

## Sponsor

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Pedram Ebrahimnejad

**Street address**

Department of pharmaceuticals, Faculty of Pharmacy,  
Mazandaran University of Medical Sciences

**City**

Sari

**Province**

Mazandaran

**Postal code**

4847193697

**Phone**

+98 11 3354 3081

**Email**

pebrahimnejad@mazums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Mazandaran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Hanieh Ahmadi

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Sport Medicine

**Street address**

Sports Medicine Department, Mostafavian Clinic, Razi  
No. 3 Alley, Razi St.

**City**

Sari

**Province**

Mazandaran

**Postal code**

4816868890

**Phone**

+98 11 3336 6552

**Fax****Email**

H.ahmadi@mazums.ac.ir

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Hanieh Ahmadi

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Sport Medicine

**Street address**

Sports Medicine Department, Mostafavian Clinic, Razi  
No. 3 Alley, Razi St.

**City**

Sari

**Province**

Mazandaran

**Postal code**

4816868890

**Phone**

+98 11 3336 6552

**Fax****Email**

H.ahmadi@mazums.ac.ir

## Person responsible for updating data

**Contact****Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Mina Ghaderi

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Sport Medicine

**Street address**

Sports Medicine Department, Mostafavian Clinic, Razi  
No. 3 Alley, Razi St.

**City**

Sari

**Province**

Mazandaran

**Postal code**

4816868890

**Phone**

+98 11 3336 6552

**Email**

minaghaderi89@gmail.com

## **Sharing plan**

### **Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

### **Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

### **Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

## **Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

### **Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

### **Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

### **Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available